Cellular adhesion molecules and peripheral arterial disease

Vascular Medicine

Volumn 11, Issue 1, 2006, Pages 39-47

  Brevetti, Gregorio ^a,b   Schiano, Vittorio ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Atherosclerosis; Cellular adhesion molecules; Intermittent claudication; Peripheral arterial disease

Indexed keywords

CELL ADHESION MOLECULE; CILOSTAZOL; IMMUNOGLOBULIN; INTEGRIN; OLIGOSACCHARIDE; PROTEIN ANTIBODY; SELECTIN;

ARTERY DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL SURFACE; CLAUDICATION; DISEASE SEVERITY; DRUG MECHANISM; EXERCISE; HUMAN; LEG ARTERY; LEUKOCYTE MIGRATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SUBENDOTHELIUM; THERAPY EFFECT;

ANGIOPLASTY, BALLOON; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; HUMANS; IMMUNOGLOBULINS; INTEGRINS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; RECURRENCE; RISK FACTORS; SELECTINS; SEVERITY OF ILLNESS INDEX;

EID: 33646135993     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x06vm645ra     Document Type: Article

References (84)

1. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85-97.
2. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
3. Tummala PE, Chen XL, Sundell CL et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-29.
4. Albaugh G, Bellavance E, Strande L, Heinburger S, Hewitt CW, Alexander JB. Nicotine induces mononuclear leukocyte adhesion and expression of adhesion molecules, VCAM and ICAM, in endothelial cells in vitro. Ann Vasc Surg 2004; 18: 302-307.
5. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102: 145-52.
6. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 19: 189-94.
7. Tenaglia AN, Buda AJ, Wilkins RG et al. Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 1997; 79: 742-47.
8. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
9. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-89.
10. Champagne B, Tremblay P, Cantin A, St Pierre Y. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol 1998; 161: 6398-405.
11. Adams DH, Mainolfi E, Elias E, Neuberger JM, Rothlein R. Detection of circulating intercellular adhesion molecule-1 after liver transplantation: evidence of local release within the liver during graft rejection. Transplantation 1993; 55: 83-87.
12. Nakai K, Itoh C, Kawazoe K et al. Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. Coron Artery Dis 1995; 6: 497-502.
13. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8: 504-12.
14. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379-87.
15. Graber N, Gopal TV, Wilson D, Beall LD, Polte T, Newman W. T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol 1990; 145: 819-30.
16. Weller PF, Rand TH, Goelz SE, Chi-Rosso G, Lobb RR. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 7430-33.
17. Bochner BS, Luscinskas FW, Gimbrone MA Jr et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991; 173: 1553-57.
18. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-54.
19. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994; 8: 929-38.
20. Rose DM, Grabovsky V, Alon R, Ginsberg MH. The affinity of integrin alpha(4)beta(1) governs lymphocyte migration. J Immunol 2001; 167: 2824-30.
21. Becker K, Kindrick D, Relton J, Harlan J, Winn R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001; 32: 206-11.
22. Schwartz EA, Bizios R, Medow MS, Gerritsen ME. Exposure of human vascular endothelial cells to sustained hydrostatic pressure stimulates proliferation. Involvement of the alpha V integrins. Circ Res 1999; 84: 315-22.
23. Hogg N, Bates PA, Harvey J. Structure and function of intercellular adhesion molecule-1. Chem Immunol 1991; 50: 98-115.
24. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178: 449-60.
25. Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992; 80: 388-95.
26. Matheny HE, Deem TL, Cook-Mills JM. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol 2000; 164: 6550-59.
27. Newton JP, Buckley CD, Jones EY, Simmons DL. Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31. J Biol Chem 1997; 272: 20555-63.
28. Boulbou MS, Koukoulis GN, Vasiou KG, Petinaki EA, Gourgoulianis KI, Fezoulidis IB. Increased soluble E-selectin levels in type 2 diabetic patients with peripheral arterial disease. Int Angiol 2004; 23: 18-24.
29. Elhadd TA, Kennedy G, Robb R, McLaren M, Jung RT, Belch JJ. Elevated soluble cell adhesion molecules E-selectin and intercellular cell adhesion molecule-1 in type-2 diabetic patients with and without asymptomatic peripheral arterial disease. Int Angiol 2004; 23: 128-33.
30. Brevetti G, De Caterina M, Martone VD et al. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. Clin Hemorheol Microcirc 2001; 24: 193-99.
31. Signorelli SS, Mazzarino MC, Di Pino L et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selecting in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003; 8: 15-19.
32. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-54.
33. Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M. P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000; 11: 723-28.
34. Koksch M, Zeiger F, Wittig K et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 2001; 21: 147-54.
35. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003; 38: 99-103.
36. Blann A, Morris J, McCollum C. Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin. Atherosclerosis 1996; 126: 227-31.
37. Kirkpatrick UJ, Mossa M, Blann AD, McCollum CN. Repeated exercise induces release of soluble P-selectin in patients with intermittent claudication. Thromb Haemost 1997; 78: 1338-42.
38. Blann AD, Seigneur M, Steiner M, Miller JP, McCollum CN. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost 1998; 79: 1080-85.
39. Brevetti G, Martone VD, de Cristofaro T et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-66.
40. Peter K, Nawroth P, Conradt C et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-12.
41. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
42. Eberhardt RT, Coffman JD. Cardiovascular morbidity and mortality in peripheral arterial disease. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 209-17.
43. Brevetti G, Piscione F, Silvestro A et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 2003; 89: 1058-63.
44. Blann AD, Seigneur M, Boisseau MR, Taberner DA, McCollum CN. Soluble P selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis 1996; 7: 789-93.
45. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916-21.
46. Silvestro A, Scopacasa F, Ruocco A et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003; 8: 225-32.
47. Fowkes FG, Allan PL, Tsampoulas C, Smith FB, Donnan PT. Validity of duplex scanning in the detection of peripheral arterial disease in the general population. Eur J Vasc Surg 1992; 6: 31-35.
48. Makin AJ, Chung NA, Silverman SH, Lip GY. Thrombogenesis and endothelial damage/dysfunction in peripheral artery disease. Relationship to ethnicity and disease severity. Thromb Res 2003; 111: 221-26.
49. Brevetti G, Corrado S, Martone VD, Di Donato A, Silvestro A, Vanni L. Microcirculation and tissue metabolism in peripheral arterial disease. Clin Hemorheol Microcirc 1999; 21: 245-54.
50. Nieman DC. Immune response to heavy exertion. J Appl Physiol 1997; 82: 1385-94.
51. Shephard RJ. Adhesion molecules, catecholamines and leucocyte redistribution during and following exercise. Sports Med 2003; 33: 261-84.
52. Neumann FJ, Waas W, Diehm C et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation 1990; 82: 922-29.
53. Silvestro A, Scopacasa F, Oliva G, de Cristofaro T, Iuliano L, Brevetti G. Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis 2002; 165: 277-83.
54. Ciuffetti G, Lombardini R, Paltriccia R, Santambrogio L, Mannarino E. Human leucocyte-endothelial interactions in peripheral arterial occlusive disease. Eur J Clin Invest 1994; 24: 65-68.
55. -/- mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000; 105: 293-300.
56. Oguchi S, Dimayuga P, Zhu J et al. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2000; 20: 1729-36.
57. Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson SR, Harker LA. Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. J Vasc Surg 1997; 26: 87-93.
58. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation 2001; 103: 2501-507.
59. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10134-39.
60. Barron MK, Lake RS, Buda AJ, Tenaglia AN. Intimal hyperplasia after balloon injury is attenuated by blocking selecting. Circulation 1997; 96: 3587-92.
61. Tsakiris DA, Tschopl M, Jager K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193-200.
62. Belch JJ, Shaw JW, Kirk G et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997; 95: 2027-31.
63. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003; 107: 1757-63.
64. Inoue T, Uchida T, Sakuma M et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004; 44: 1408-14.
65. Regensteiner JG, Ware JE Jr, McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-46.
66. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
67. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
68. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
69. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-95.
70. Blankenberg S, Rupprecht HJ, Bickel C et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42.
71. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-27.
72. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-25.
73. Gaetani E, Flex A, Pola R et al. The K469E polymorphism of the ICAM-1 gene is a risk factor for peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2002; 13: 483-88.
74. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-83.
75. Silvestro A, Brevetti G, Schiano V, Scopacasa F, Chiariello M. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005; 93: 559-63.
76. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
77. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
78. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
79. Ohta T, Saku K, Takata K, Adachi N. Soluble vascular cell-adhesion molecule-1 and soluble intercellular adhesion molecule-1 correlate with lipid and apolipoprotein risk factors for coronary artery disease in children. Eur J Pediatr 1999; 158: 592-98.
80. Brevetti G, Martone VD, Perna S et al. Intermittent claudication and risk of cardiovascular event. Angiology 1998; 49: 843-48.
81. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.
82. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-98.
83. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
84. Douglas JS, Weintraub WS, Holmes D. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. Clin Cardiol 2003; 26: 451-54.